Clinical Feasibility of Monitoring Enoxaparin Anti-Xa Concentrations: Are We Getting It Right?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

1. Molecular biomarkers in dialysis-related thrombosis and anticoagulation monitoring: thrombin-antithrombin complex, plasmin-α2-antiplasmin complex, soluble thrombomodulin, tPA/PAI-1/tPAIC, and Anti-Xa.Frontiers in medicine · 2026
   Review
2. Diagnosis and management of ACS in patients with ESRD on haemodialysis: a comprehensive review.The British journal of cardiology · 2025
   Article
3. The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients.European journal of clinical pharmacology · 2023
   Article
4. Optimal Dosing of Enoxaparin in Critically Ill Patients with Venous Thromboembolism.Innovations in pharmacy · 2023
   Article
5. Use of Real-World Data and Physiologically-Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With Obesity.Clinical pharmacology and therapeutics · 2022
   Article
6. Adequate Antithrombin III Level Predicts Survival in Severe COVID-19 Pneumonia.Cureus · 2021
   Article
7. Heparins have adequate ex vivo anticoagulant effects in hospitalized patients with cirrhosis.Journal of thrombosis and haemostasis : JTH · 2021
   Article
8. Evaluation of Anticoagulant Monitoring in Pediatric Patients Receiving Enoxaparin for Treatment of Venous Thrombosis.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021
   Article
9. Hypercoagulopathy in Severe COVID-19: Implications for Acute Care.Thrombosis and haemostasis · 2020
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors at 3 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as